COVAXX’s UB-612 program focuses on developing its Multitope Peptide-based Vaccine against SARS-CoV-2, constructed from a peptide-based platform first deployed by parent company United Biomedical. COVAXX has launched a Phase I trial of UB-612 in Taiwan, with a U.S. Phase I trial and a readout of data in non-human primates planned this fall . . .
- Virology
- Coronavirus
- Drug Discovery
- Vaccine Development
- GEN Edge
- Molecular Diagnostics/In vitro Diagnostics
- T Cells
Beyond the Spike: The COVAXX Approach to a COVID-19 Vaccine
COVAXX looks beyond the Spike protein as it combats SARS-CoV-2 by targeting multiple epitopes
[National Institute of Allergy and Infectious Diseases, NIH]